instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: Employees of Novartis Pharma K.K. (NPKK) transferred some data from research centers to a Tokyo hospital when that data should have been sent directly without first passing through Novartis hands, according to a report by Japanese broadcaster NHK that was picked up by the Wall Street Journal. "NPKK is currently investigating the allegations," Novartis said in a statement. The data was from a not yet fully enrolled 55-patient trial testing the Novartis cancer drug Tasigna, the company said. "Novartis Pharma K.K. is aware of the media report regarding a small investigator-initiated clinical study ... conducted to assess side effects in patients with chronic myelocytic leukemia," Novartis said in a statement. "NPKK has conducted employee trainings on proper protocol related to investigator-initiated clinical studies and believes that any involvement of our medical representatives in investigator-initiated clinical studies is inappropriate." The University of Tokyo Hospital said it was re-examining test results it had received but had uncovered no evidence that Novartis employees had manipulated any of the data during the transfers, according to the Wall Street Journal report. Claim: Novartis employees may have violated trial protocol in Japan.
answer:
Swiss drugmaker Novartis said on Friday it was looking into a report that employees of is Japanese unit may have violated clinical trial protocol by handling data from a small independent study of one of its cancer drugs.

question:
Paragraph: We'll give this story a Satisfactory rating in this category since it does mention the $1,000 cost of a colonoscopy and that one of the two at-home screening tests costs about $25. But readers would benefit more by knowing the average costs of the two alternatives, rather than just the cost of one. This story focuses on theavailable methods of colorectal screening, comparing them based on available data, and points out that the two at-home screening kits are comparably effective to the two invasive procedures: sigmoidoscopy and colonoscopy. One of the at-home tests the FIT, or fecal immunochemical test when used, is estimated to prevent 20-23 deaths per thousand people screened, while estimates among those using colonoscopy suggest 22-24 deaths are prevented per thousand people screened. The story is clear in saying that there has been no head-to-head comparative study pitting the techniques against each other. The story gets a Satisfactory rating here since it does mention that with colonoscopy, there's "a small but real risk of harm, such as a perforation" from the screening test. But, as with all screening methods, there is the possibility of false positives or false negatives with the at-home tests which could produce either false confidence or needless worry, not insignificant issues. We would have liked the story even better had it mentioned these factors. The story is quite open with the fact that comparative data assessing the various screening methods against each other are not available, but it strengthens its offerings by citing recommendations from both the US Preventive Services Task Force and the Canadian Task Force on Preventive HealthCare. The recommendations of these independent groups are based on a rigorous evaluation of the highest-quality evidence available. Colon cancer is the second-leading form of cancer-related death in the country; the story does not disease monger. The story quotes three independent sources for information and the recommendations of agencies from two different governments. There is no suggestion that in a story offering a selection of screening techniques, with no one preferred above another, that there is any issue with conflicts of interest. Since this story is totally about the available alternatives for colorectal cancer screening, it easily gets a Satisfactory rating. Both colonoscopy and sigmoidoscopy have been available for years and the at-home screening tests mentioned in the story are said to be available through a patient's doctor's office. These details establish the methods' availability. It also quotes one source asrecommending againstthe use of over-the-counter home screening tests for this disease. The story notes that what's novel here is that the U.S. Preventive Task Force recently finalized their guidelines on colon cancer screening. There is no indication that this story relied on a news release. Claim: You Could Skip Your Colonoscopy If You're Willing To Collect Your Poop
answer:
This story points out that, based on available data, two at-home screening tests appear to be equally effective compared to the more traditional, and more invasive, sigmoidoscopy and colonoscopy. We have only minor quibbles with the storyoverall, it provided an excellent assessment of the at-home test options, particularly the fecal immunochemical test. However, for any story about screening methods, particularly blood tests, we think it's important to include the risks of false-positive and false-negative results, which carry harm. The story didn't go there. Given that the public has reservations about aspects of the invasive screening methods, information suggesting that they might be adequately replaced by non-invasive approaches is important to the public's health. All too often, colonoscopy is promoted as the "gold standard"and no mention is made of effective alternatives. This news storydoes a good job explaining options, and also explores the reasons why so many Americans think that screening with colonoscopy is the best way to be screened for colon cancer and why that attitude is not supported by the evidence and may (in rare cases) be much worse than non-invasive screening methods.

question:
Paragraph: Previous studies have established a heightened risk for fractures among patients taking both medicines, since they may cause slower bone formation and faster bone loss. The new research sheds light on the scale of the problem by comparing the records of 1,020 diabetic patients with fractures diagnosed by British doctors between 1994 and 2005 against a control group of diabetics who did not have fractures. Christian Meier of University Hospital Basel found those on Avandia or Actos known generically as rosiglitazone and pioglitazone had double or triple the odds of non-spine fractures. The odds for fracture were increased among patients who took the drugs for approximately 12 to 18 months and the risk was highest for those with two or more years of therapy. Fractures of the hip and wrist were most notable, according to the findings published in the journal Archives of Internal Medicine. Avandia and Actos belong to a class of medicines called thiazolidinediones, which are designed to sensitise the body to insulin. But researchers believe they also stimulate the action of a cell that drives the process of reabsorbing bone, making bones more apt to break. Both are blockbuster products but Avandia has lost out to Actos following publication of a U.S. study last May linking it to heart attack risk. Claim: Swiss study suggests diabetes drugs double fracture risk.
answer:
Diabetes drugs Avandia from GlaxoSmithKline Plc and Takeda Pharmaceutical Co Ltd's Actos can more than double the risk of bone fractures, Swiss researchers said on Monday.